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Abstract: Corneal blindness affects over 10 million people worldwide and current treatment 
strategies often involve replacement of the defective layer with healthy tissue. Due to a 
worldwide donor cornea shortage and the absence of suitable biological scaffolds, recent 
research has focused on the development of tissue engineering techniques to create 
alternative therapies. This review will detail how we have refined the simple engineering 
technique of plastic compression of collagen to a process we now call Real Architecture for 
3D Tissues (RAFT). The RAFT production process has been standardised, and steps have 
been taken to consider Good Manufacturing Practice compliance. The evolution of this 
process has allowed us to create biomimetic epithelial and endothelial tissue equivalents 
suitable for transplantation and ideal for studying cell-cell interactions in vitro. 
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1. The Cornea and Limbus  
At the front of the eye the crystal-clear cornea is exquisitely designed to combine two important 
functions. The cornea provides the majority of the eye’s focusing power and it also protects the eye, 
resisting physical insults and preventing entrance of debris and infection. To perform these roles the 
cornea combines durability and strength with glass-like transparency and smoothness. To maintain 
clarity the cornea must resist inflammation, vascularization, and invasion by surrounding cells and this 
requires continuous active participation from the different parts forming this deceptively simple structure.  
The cornea comprises five layers; stratified epithelium covers the anterior corneal surface facing the 
external environment, it provides a barrier to infection and permits the flow of fluids and nutrients from 
the tear film to the main body of the cornea, the stroma or substantia propria. Between the stroma and 
the epithelium is the Bowman’s membrane, a layer of extracellular protein containing the sub-basal 
nerves. The stroma itself is a highly ordered collagen structure, produced by keratocytes, the resident 
cells of the stroma and transparency depends on keratocytes remaining quiescent. At its posterior face 
the cornea is lined with a specialised endothelium which maintains the stromal hydration levels and thus 
clarity by pumping fluid out of the stroma into the anterior chamber when required. The endothelium 
sits on the Descemet’s membrane (DM), another extracellular matrix layer lying between the stroma and 
the endothelium, it is secreted by the endothelium and essential for endothelial integrity (Figure 1). 
 
Figure 1. Haematoxylin and eosin stained section of human cornea comprising five layers. 
At the corneal periphery where the stroma attaches to the tough, white fibrous membranes of the 
sclera and the clear corneal epithelium gives way to the opaque mucous-secreting conjunctival 
epithelium, lies the corneoscleral junction or limbus, a unique region with remarkable properties. The 
limbus provides a rich environment where the stem cells necessary for normal turnover of the corneal 
epithelium and their support cells reside [1]. In addition, stem cells that are the precursor cells for stromal 
keratocytes are found near the limbus [2]. The limbus is richly vascularised and contains many 
myelinated nerves, interestingly the limbus appears to create a barrier, as on its corneal side there are no 
blood vessels or myelinated nerves. The limbal epithelial stem cells (LESCs) reside in a specialised  
3D microenvironment, physically protected from surface insult by lying deep within structures termed 
limbal crypts (LCs) [3], which are the valleys formed between stromal ridges. The LCs are 
predominantly located at the superior and inferior regions of the limbus where cells are afforded 
additional protection from the eyelids [4].  
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2. Limbal Stem Cell Deficiency  
Minor surface injuries to the cornea generally heal well in the healthy eye. In cases where the LESCs 
are compromised or lost, however, conjunctival epithelial growth extends beyond the limbal barrier, 
replacing the corneal epithelium with an opaque layer that is irregular and heavily vascularised, a painful 
condition that leads to sight loss. Limbal epithelial stem cell deficiency (LESCD) can be the result of 
damage to the eye following physical trauma, burn or chemical insult, a genetic disorder, as seen in 
aniridia generally caused by loss of function of the PAX6 gene [5] or other diseases such as the 
autoimmune Stevens-Johnson syndrome [1,6].  
3. Current Treatments for Limbal Stem Cell Deficiency  
Grafts of LESCs can be applied to the corneal surface to treat patients with LESCD. To prepare the 
cornea before placing the graft and to improve the chances of graft survival the surface of the cornea 
must be repaired by removal of the conjunctiva from the corneal wound bed and inflammation controlled 
before delivering the LESCs. Donor stem cells are then attached to the front of the eye and cells can be 
applied directly as tissue grafts or after in vitro expansion. Cultured LESCs can be applied simply as a 
sheet of cells, or prepared on a scaffold that is grafted on to the ocular surface with the cells attached. 
Human amniotic membrane (HAM) and fibrin are both commonly used as scaffolds to deliver LESCs 
to the corneal surface in the clinic [7,8]. HAM is prepared from donated tissue after elective caesarean 
section. It has been widely used as a carrier for limbal stem cell grafts as it provides an efficient scaffold 
for cell seeding and has other beneficial biological properties including anti-inflammatory, anti-microbial, 
anti-fibrotic, anti-scarring, and low immunogenicity, as well as good mechanical properties. 
4. Drawbacks to Current Treatment Strategies  
HAM is highly biologically variable [9] and often grafts destined for patient transplantation have to 
be discarded due to lack of limbal epithelial stem cell growth on the surface. HAM also has the potential 
to carry infection, and so must undergo screening before use, and, thus, is sub-optimal for cell therapy 
Good Manufacturing Practice (GMP) compliance. A biomimetic replacement for HAM would address 
an unmet clinical need and improve availability of treatment, as supplies of suitably processed HAM are 
limited. Fibrin gels provide a good alternative substrate for limbal epithelial stem cell growth and can 
be used as a carrier for graft cells. However, their degradation rate must be tightly controlled with the 
addition of anti-fibrinolytics [10]. 
5. Requirements for a Successful Cell Carrier 
The essential properties of a cell carrier include optimal human limbal epithelial (hLE) cell culture 
and attachment to the surface, it must be capable of being attached to the cornea by sutures or fibrin glue 
and once on the eye it should either be resorbed, leaving cells well attached (fibrin) or become transparent 
in situ (HAM). Most importantly, it is essential that a proposed carrier does not initiate an inflammatory 
reaction in the corneal surface that might trigger scarring and haze in the stroma. Where the eye surface 
is damaged, the use of a scaffold like HAM with considerable mechanical strength can help to stabilise 
the ocular surface, as well as acting as a delivery vehicle for therapeutic stem cells. Graft cells can be of 
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limbal origin and either autologous or allogeneic. Autologous is preferable and possible if one healthy 
eye remains but allogeneic cells are required from a suitable donor if the damage is bilateral leaving no 
healthy limbus for autograft. In addition, successful grafts have been made from other stem cell sources, 
notably from oral mucosal epithelium [11].  
6. Alternative Cell Carriers for Transplantation  
In addition to HAM and fibrin, many biomaterials and synthetic polymers have been developed with 
a view to making tissue equivalent scaffolds for delivering stem cells and for surface repair in the cornea. 
These include keratin, silk fibroin, chitosan hydrogels [12], siloxanehydrogel contact lenses, thermo 
reversible polymers [13] and nanofibre scaffolds, recently reviewed by He and Yiu [14] and Feng et al. [15]. 
In addition to these alternatives, extracellular matrix (ECM) based scaffolds can act as suitable substrates 
for tissue engineering due to their inherent properties of biocompatibility and degradability. Collagen is 
the most abundant ECM protein in the human body, providing structural support and strength to various 
tissues. Specifically, type I collagen is the most abundant collagen of the cornea, and its highly organised 
collagen ultrastructure is crucial in providing structural support and transparency to the tissue. Type I 
collagen has widespread use in tissue engineering applications due to its abundance, ease of extraction 
and adaptability for multiple applications [16]. We describe here our efforts over the preceding six years 
to develop a novel collagen-based tissue engineering approach that is applicable to the treatment of 
corneal defects in both the epithelium and endothelium.  
Table 1. Summary of advantages and disadvantages of various alternative scaffolds  
for transplantation. 
Scaffolds Advantages Disadvantages 
Keratin 
good transparency; 
good mechanical strength; 
good availability 
limited elasticity; 
no in vivo data; 
no data regarding clinical efficacy; 
cannot incorporate cells within 
Silk fibroin 
non-immunogenic; 
degrades in vivo; 
biocompatible; 
good transparency; 
good mechanical strength; 
well characterised (already used as a suture material); 
good surface for hLE cell expansion in vitro 
costly to produce; 
no data regarding clinical efficacy; 
cannot incorporate cells within 
Siloxane 
hydrogel  
good mechanical properties 
good transparency 
well characterised (already used as contact lenses) 
good surface for hLE cell expansion in vitro 
clinical data is encouraging 
cannot incorporate cells within 
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Table 1. Cont. 
Scaffolds Advantages Disadvantages 
Fibrin 
good mechanical properties; 
degrades in vivo; 
good surface for hLE cell expansion in vitro; 
clinical data is encouraging; 
could potentially be an autologous therapy 
reported transparencies vary; 
risk of disease transmission; 
cannot incorporate cells within; 
some evidence to suggest that hLE 
differentiation is promoted on fibrin 
Thermo 
reversible 
polymers 
good surface for hLE cell expansion in vitro; 
simple process to harvest hLE cell sheet 
hLE must be transplanted as a sheet, 
surgically complex; 
cannot incorporate cells within 
Nanofibre 
scaffolds 
good mechanical properties; 
good transparency; 
good surface for hLE cell expansion in vitro; 
may degrade in vivo 
no data regarding clinical efficacy; 
mechanical properties may change 
throughout hLE culture period; 
cannot incorporate cells within 
Chitosan 
hydrogels 
well characterised (already used as wound dressing); 
good mechanical properties 
limited transparency; 
cannot incorporate cells within; 
methods used to improve mechanical 
properties may increase cytotoxicity 
7. Plastic Compressed Collagen  
Cellular type I collagen hydrogels have previously been used as 3D substrates for cell culture and 
creation of corneal models. However, because they are composed of a high proportion of water they are 
intrinsically weak unless modified with chemical crosslinking or blended with other polymers to create 
collagen composites, preventing direct seeding of cells within the scaffold [17–19]. To overcome this 
problem, Brown and colleagues developed a novel method of plastic compression of type I collagen 
hydrogels by applying simple engineering techniques such as external mechanical loading and capillary 
fluid flow (Patent number WO2012004564) [20,21]. Hyperhydrated collagen gels are composed of a 
mesh of collagen fibrils supporting a large volume of excess fluid (99%). Hydrogels were produced by 
neutralising a mix of acetic acid based rat-tail type I collagen and 10× minimum essential medium 
(included as an indicator of pH and to ensure physiological ionic strength for cell compatibility and 
standardised collagen fibril formation) with sodium hydroxide. Liquid was then cast into moulds and 
set/stabilized at 37 °C. In their method, hydrogels were subjected to an unconfined compression by 
placing the gel on top of a series of nylon and stainless steel meshes and blotting filter papers with 
addition of a load (Figure 2A). The key feature of this process is that the expulsion of this liquid does 
not return on the removal of the load, hence the hydrogel undergoes plastic compression (PC) in an 
unconfined manner. One major advantage of this method is that cells can be seeded into the body of the 
hydrogel before compression and therefore production of a cell seeded scaffold is ultrarapid, taking just 
minutes and without loss of cell viability. The use of plastic compressed collagen as a substrate/scaffold 
has been proposed for many tissue engineering applications, including bone [22], skin [23], nerve [24], 
bladder [25], and microvascular endothelium [26].  
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Figure 2. Evolution of the RAFT tissue engineering procedure. (A) Schematic diagram of 
original plastic compression process with application of a load for unconfined compression 
and downward fluid flow; (B) Confined compression in a well plate with upward flow on 
application of a load; (C) Current RAFT process with gentle wicking of fluid into HPAs in 
a confined manner with no addition of a significant load. 
We exploited the Brown method to produce a novel substrate for hLE cell expansion and stratification 
into a corneal epithelial tissue equivalent (TE) [27]. Collagen type I hydrogels were subjected to a 
process of PC as seen in Figure 2A. In order to determine the importance to the epithelial layer of closely 
associated stromal cells, we compared acellular constructs with those containing human limbal 
fibroblasts (hLFs) in the body of the construct, mimicking the hLF populated anterior stroma of the 
cornea. These cells were mixed directly into the collagen hydrogel solution before setting and compression. 
hLE cells were then seeded onto the surface of the constructs and allowed to expand and stratify over a 
period of three weeks. The resulting corneal epithelial TE’s displayed many of the characteristics of 
human corneal epithelium. These included typical morphological organisation of cuboidal basal cells 
with high levels of putative stem cell marker (p63α) expression, squamous superficial cells with high 
levels of CK3 expression and appropriate basement membrane protein deposition. The hLF containing 
constructs displayed increased biomimicity suggesting an interaction between hLF and hLE cells. The 
resulting TEs provide an ideal model for studying cell-cell interactions in the anterior cornea and made 
steps towards development of a suitable alternative to HAM for hLE cell transplantation for ocular 
surface repair.  
Although this technique fulfilled many of the criteria for a successful alternative substrate for HAM 
including ease and speed of preparation and relative transparency there was a major drawback associated 
with this method because of the unconfined nature of the compression process. This meant that fluid loss 
was not controlled and, thus, the procedure was practically messy and, thus, did not comply with the 
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rigorous GMP standards required for production of a cell therapy. Secondly, in this format the method 
was difficult to scale up for easy production of multiple constructs, therefore, we went on to modify the 
process in order to make steps towards GMP compliance and scalability. 
8. The Early RAFT Process  
In collaboration with a SME (small and medium sized enterprise; TAP Biosystems), we developed 
what we now refer to as the Real Architecture For 3D Tissues (RAFT) process by extensive modification 
of the original PC process from a variable hand-made research method [20] to an improved, reproducible 
process suitable for clinical application [28]. The differences between the three iterations of the process 
are summarised in Table 2. The original unconfined compression (UC) process was not tightly controlled 
and therefore not compatible for use in a GMP clean room facility. In particular, this process had a 
greater potential for production of aerosols and particulates, which is not ideal for a GMP compliant 
approach. Additionally, the final product had inconsistent dimensions due to fluid loss in various 
directions. To overcome these issues, the collagen hydrogel mixture was cast, set and compressed in a 
confined manner using a custom-made cassette or 12-well plate format (Figure 3A,B). The modification 
involved a change in the direction of fluid removal to one of upward flow using a rolled filter paper 
absorber and other blotting elements placed on the top surface of collagen hydrogels for 15 min at room 
temperature (Figure 2B and Table 2). As a weight was applied, hydrogels still underwent compression 
but this time it was a confined compression (CC), which reduced the risk of aerosol and particulate 
production. Following compression, RAFT TEs were ready in a multi-well plate format or an individual 
cassette for immediate analysis or subsequent culture of cells. This reduced the risk of damaging RAFT 
TEs during handling or transfer from one vessel to another as was required for the original PC method.  
Table 2. Summary of the three iterations of our tissue engineering protocol. 
Iterations Fluid removal method 
Fluid removal 
direction 
Confined or 
unconfined 
Absorbent material 
Plastic compression Compression with load Downward Unconfined Filter paper 
Early RAFT Compression with load Upward Confined Filter paper 
Late RAFT Absorption Upward Confined Hydrophilic porous absorber 
 
Figure 3. Evolution of the RAFT process hardware. (A) Individual cassette for upward 
confined compression method; (B) Paper rolls and weights used for 12 well plate confined 
compression method using upward flow; (C) Commercially available RAFT kits including 
reagents, plates and plate heater (image reprinted with permission of TAP Biosystems);  
(D) 24-well plate array of HPAs. 
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We investigated whether these modifications (from UC to CC) affected the properties of RAFT TEs 
and their ability to act as a substrate for culture of hLE cells [28]. Comparison of RAFT TEs prepared 
with either UC or CC revealed no differences in hLE cell morphology or phenotype. hLE cells remained 
small in size with characteristic cobblestone morphology and expressed putative stem cell marker p63α 
and differentiated epithelial cell marker CK15. Cells also expressed features similar to mature human 
corneal epithelium (CK3). There were no significant differences in the light transmission properties, 
handling and cell viability of RAFT TEs produced using UC and CC processes. The thickness of RAFT 
TEs was the only parameter that was significantly different, with thicker substrates produced by the UC 
process. However, a change in this property did not adversely affect the function of RAFT TEs as a 
substrate for hLE cell culture and was thought to be due to an increased wicking power in the CC process 
resulting in greater fluid loss and a thinner TE. Importantly, the thickness of RAFT TEs produced with 
CC was consistent, unlike HAM, which varies greatly ranging from 20–130 μm [29–31]. 
We also described the first use of RAFT TEs, prepared using CC, to successfully support the culture 
of primary human corneal endothelial cells (hCECs) in addition to corneal endothelial cell lines [32]. 
Corneal blindness caused by a dysfunctional endothelial layer was previously treated by full thickness 
corneal replacement surgery but recent advancements in surgical techniques allow the replacement of 
only the affected endothelial layer. One such example is replacement of a defective endothelium with a 
Descemet’s Membrane Endothelial Keratoplasty (DMEK) graft, a technique that delivers a healthy 
endothelial cell layer attached to just the delicate DM layer obtained from a donor cornea [33]. However, 
there is currently a worldwide donor shortage of clinical quality corneas that greatly increases patient 
waiting times for such procedures and this has led to considerable interest in the development of 
alternative tissue engineering approachs to treat such corneal defects [34]. hCECs cultured on RAFT 
TEs retained their endothelial characteristics, remaining small and with cobblestone morphology and 
expressed ZO-1 and Na+/K+ ATPase; markers typically used for the identification of hCECs. They were 
also easy to handle and demonstrated sufficient mechanical strength for delivery into the anterior 
chamber of an ex vivo porcine eye, indicating suitability for transplantation. This approach has great 
potential to improve clinical practice as only one human donor cornea is required to obtain a sufficient 
number of hCECs to treat multiple patients, unlike the full thickness or DMEK grafts described earlier 
that require one donor per recipient.  
The advantages of the CC RAFT process included simple, rapid production of multiple TEs with 
limited variation, as well as making considerable progress towards GMP compliance. The use of 
individual cassettes was ideal for preparation of patient grafts for transplantation because all three 
elements of manufacture, cell culture, and TE transport to theatre were performed within the same vessel. 
The use of commercially available multi-well plates to perform the RAFT process made it an attractive 
approach for pharmacological testing of substances on multiple TEs. It also enabled the process to be 
scaled up into 24-well and 96-well plate formats, further reducing preparation time without 
compromising reproducibility. 
9. Improved Good Manufacturing Practice Compatibility of RAFT 
Cell therapy products must be manufactured within a specialised cleanroom laboratory in compliance 
with GMP [35]. The specific considerations around the design of equipment and processes used in GMP 
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manufacture include the following; the manufacturing process must be reproducible, time-effective, 
generate a consistent end-product and utilise equipment compatible with cleanroom use and cleaning 
methods. The process must also include measures to prevent microorganism contamination, such as the 
use of one-use reagents, smooth-surfaced and low particle shedding materials, and must not present risk 
to the patient through adventitious agent transmission [35,36]. Therefore, our previous RAFT process 
was even further modified to its current commercially available form with the above GMP considerations 
in mind. 
The commercially available RAFT kit is provided with validated protocols that are simple to use and 
a 37 °C plate heater for standardised hydrogel setting and TE formation (Figure 3C). The whole process 
is robust, reproducible and allows for the manufacture of multiple consistent RAFT TEs. The process is 
rapid; from initial set-up to the generation of the RAFT TE takes as little as 90 min which is an 
advantageous attribute for GMP manufacturing. This is because in order to comply with health and safety 
guidelines, operators are designated a maximum processing time. Additionally, GMP grade manufacturing 
is inherently costly so any reduction in facility costs is preferable. 
The casting of collagen hydrogels in commercially available well plates remains consistent with the 
previous iteration of the method. However, instead of the CC process, a gentle wicking process is 
employed whereby water is absorbed through an upward flow capillary action into hydrophilic porous 
absorbers (HPAs) (Figures 2C, 3D and Table 2). Therefore, the process is no longer one of compression 
as no significant load is added, only the minimal weight of the HPA itself; fluid is lost through gentle 
absorption alone. This containment of fluid further minimises contamination risk in keeping with GMP 
requirements. In addition, the simplification of the procedure provided by the use of disposable HPAs 
and elimination of re-useable weights, is more appropriate for processing in a GMP environment.  
The HPAs are manufactured from porous sintered polymers and contain a standardised pore size 
optimised to efficiently absorb liquid. Additionally, HPA polymer materials are non-particle shedding 
therefore minimising potential contamination risk. The moulding process produces HPAs of a standard 
size (compatible with 24-well and 96-well plates) and allows for reproducible RAFT TE size every 
application (Figure 3D). The HPAs are supplied sterile and individually packaged to give ultimate 
flexibility in producing the number of TEs required without wastage of materials. The RAFT plate heater 
has been designed with a small footprint to fit through cleanroom hatches and inside biological safety 
cabinets, and also contains smooth surfaces to allow efficient cleaning. The 96-well plate format, 
available in both clear and black bottomed varieties, allows for a broad range of applications and the 
production of multiple RAFT TEs per manufacturing session. The supplied reagents for such an 
application, e.g., type I collagen, neutralising solution and 10X MEM, are designed for “one-use” only 
in order to prevent potential contamination risks posed through aliquoting manipulations and storage.  
An important consideration in the development of RAFT reagents was to ensure adherence to EU 
legislation on the use of animal-derived materials during GMP manufacture [35,36]. Biologically 
sourced materials may pose increased risk through transfer of adventitious agents such as bacteria, 
viruses or prions, therefore legislation dictates that such materials must be carefully risk-assessed 
including how they demonstrate compliance to prescribed controls. RAFT type I collagen has undergone 
such risk assessments and has been classified “Transmissible Spongiform Encephalopathies (TSE) 
compliant”, where risk of transmission of TSE-causing agents is negligible due to the sourcing of 
animals from closed herds and from a country with negligible Bovine Spongiform Encephalopathies 
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(BSE) risk. With respect to concerns of potential viral and bacterial contamination, the herds are 
screened, certified free from infectious disease and classified fit for human consumption. The collagen 
reagent itself is provided with quality documentation to demonstrate animal country of origin, TSE 
compliance and product specification, all of which are necessary documentation for materials involved 
in GMP manufacture. Each component part of the RAFT process has been assessed and essential GMP 
criteria have been considered at each developmental stage.  
10. Recreating the Limbal Epithelial Stem Cell Niche Using RAFT 
We have previously used the RAFT system to create relatively simple central corneal TEs but the 
flexibility of the HPA system allows us to also create some of the features of the complex hLESC niche. 
The ability to design and engineer artificial stem cell niches has allowed researchers to simplify elements 
of complex environments for in vitro study and also to maximise the therapeutic potential of stem cells 
for repair strategies. As previously described, the LESCs reside at the base of the LCs in a physically 
protected position predominantly at the superior and inferior regions of the limbus [3] and so we 
hypothesised that culture of cells in a recreation of that physical environment could increase hLESC 
potency. By studying native LCs in human corneas we were able to determine average dimensions of 
the LESC filled stromal structures, which are approximately 110 μm wide and 70 μm deep. The 
moulding method of manufacture of the HPAs enables surface topography to be incorporated into the 
HPA surface that will contact the collagen gel. We created ridged HPAs (RHPAs) with micro-ridges of 
varying width and depth (100–250 μm; Figure 4A) to determine the most suitable size to create features 
in the RAFT TE surface that would mimic the native LCs. We determined that RHPAs with 175 μm 
micro-ridges would create bioengineered limbal crypts (BLCs) of the desired dimensions and so created 
HPAs with ridges across the entire surface (Figure 4B). The BLCs remained stable in culture (Figure 4C) 
and in the presence of hLFs in the stromal portion of the RAFT TE and with hLECs on the surface [37]. 
Human corneal cell line cells populated the BLCs (Figure 4D) and hLECs also multi-layered to fill the 
BLCs with cells at the base expressing putative LESC markers as well as appropriate basement 
membrane proteins. Interestingly, hLFs in the stromal portion of the RAFT TE aligned and elongated 
along the length of the BLCs (unpublished observations), which mimics the arrangement of stromal cells 
in this region in close proximity to the native LCs.  
 
Figure 4. Creation of bioengineered limbal crypts using RAFT. (A) SEM image of the base 
of a RHPA showing microridges; (B) Base of HPA (left) and RHPA (right); (C) BLCs created 
in the surface of the RAFT TE filled with fluorescent microspheres; (D) Human corneal 
epithelial cell line cells stained with haematoxylin and eosin filling a BLC in a RAFT TE. 
Scale bars: (A,C), 100 μm; (D), 50 μm. 
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Using the RAFT system we can rapidly and reliably recreate the 3D physical structures of the LESC 
niche in as little as 90 minutes, an improvement on other lengthier approaches [38,39]. Mimicking the 
elements of the niche will allow investigators to study cell-cell and cell-matrix interactions in a more 
biomimetic environment and could potentially increase the chances of success of cell based therapy by 
maintenance of critical stem cell populations.  
11. Clinical Application of RAFT  
The ultimate goal of our research is to treat patients suffering from LESCD. Whilst this has always 
been a consideration during the development of the RAFT process, in order to be clinically applicable, 
further considerations must be made. The current “gold standard” substrate for LESC transplantation is 
HAM [40–42], despite the disadvantages outlined earlier. RAFT TEs are reproducible, quick to 
manufacture, do not require the expensive screening required for human tissue and reliably support hLE 
cell growth in vitro [27,37], all evidence to support the use of RAFT TEs over HAM for ocular  
surface repair. 
During RAFT process development, the initial focus was to optimize hLE cell growth on the surface 
of the collagen, as opposed to end user requirements such as thickness, transparency and strength. The 
thickness of the substrate is important so as not to cause discomfort to the recipient or complicate the 
surgical procedure. Similarly, light transmission is important to provide the recipient with the best 
possible visual acuity post-transplantation. Although collagenous RAFT TEs may undergo some degree 
of degradation post-transplantation, at present we have no in vivo data to support this, so optimal 
transparency from the outset is desirable. Finally, RAFT TEs should have sufficient mechanical strength 
to withstand handling and attachment to an eye using fibrin glue or similar. 
One great advantage of the RAFT TE production process is that it is readily tunable. Since the 
concentration and volume of collagen used to produce the hydrogel can be varied, RAFT TEs with a 
variety of properties can be produced after fluid absorption using the HPAs. RAFT TEs can be produced 
which have thicknesses ranging from approximately 50 μm to more than 400 μm. Light transmission at 
550 nm (the middle of the visible wavelength range) through RAFT TEs can exceed 80%. Whilst under 
tension, RAFT TE break stresses are comparable to that of HAM. HAM is already established as a 
substrate, albeit sub-optimal, for LESC transplantation and we have shown that RAFT TEs of 
comparable thickness, transparency and strength can be produced, but with additional advantages as 
outlined above. Additionally, unlike HAM, RAFT TEs display shape memory, which may ease surgical 
delivery to the ocular surface. 
Along with the RAFT TE substrate, the cells themselves should be fit for purpose. For Advanced 
Therapy Medicinal Products (ATMP), this is normally determined using a reference standard or potency 
assay. A reference standard provides a comparator with which all manufactured batches can be compared 
to confirm that the manufacturing process is proceeding as intended/required. For RAFT TEs, we have 
demonstrated that hLE cell size, morphology, putative stem cell marker expression (p63α) and ability to 
form a stratified epithelium could be used as part of a reference standard [43]. A correlation between 
expression of p63α and clinical outcome has also been suggested by others [44], further supporting the 
use of p63α expression as part of a reference standard. When producing an autologous treatment, this 
can be complex as only a limited numbers of cells are available but by observing the hLE cells during 
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culture using light microscopy, progress can be assessed using a simple, non-destructive method. 
Throughout the culture period individual cultures on RAFT TEs may be compared with light microscopy 
images of the reference standard for assessment of confluency. Beyond this, a potency assay provides a 
means of testing the function of the ATMP. hLE cells on RAFT should function to protect the underlying 
stroma by maintaining a continuous barrier. To test hLE cell function, we used two wounding regimes: 
an Algerbrush II corneal rust ring remover to produce a 1 mm stripe defect [43]; and a heptanol-soaked 
paper disc to produce a larger 20 mm2 circular defect [45]. We found that hLE cells on RAFT were 
reliably able to close the stripe defect, although p63α expression was decreased following 
wounding [43]. This is important as this provides evidence that hLE cells are sufficiently potent to be 
clinically useful. We also assessed the impact of the presence of hLFs on hLE cell function and also the 
impact of airlifting using the heptanol wounding regime. We found that hLFs do not improve hLE cell 
potency with respect to wounding (although hLFs do confer other benefits to overlying hLE cell layers 
as described earlier). However, we did find that hLE cells in a stratified epithelium displayed reduced 
cell function compared to cells in a monolayer, leading us to believe that transplantation of a monolayer 
of hLE cells on RAFT TEs would be the optimal approach [45]. 
12. Summary 
Corneal disease and disorder is the cause of blindness in over 10 million people worldwide. A lack 
of suitable donor tissue has lead to increased interest in the development of tissue engineering strategies 
to construct tissue equivalent layers of the cornea to replace the defective regions. Here we have 
described the development of our RAFT tissue engineering process that aims to tackle this very problem. 
Our final RAFT process is very far removed from the original plastic compression process, which 
required six component parts. After modification of the flow removal method, direction, containment, 
and absorber material the process now only requires one component, the HPA, to transform a 
hyperhydrated collagen hydrogel into a mechanically stable substrate for cell growth. This simplification 
of the method meant that we were able to take considerable steps towards GMP compliance and clinical 
applicability. We have shown that this method is suitable for the production of both corneal epithelial 
and endothelial TEs which may be suitable for transplantation. Furthermore, the tunable nature of the 
HPA production method allowed us to create surface topography in the TEs to rapidly and reliably 
recreate LESC niche features, the LCs of the cornea. This will allow researchers to study cell-cell and 
cell-matrix interactions of the LESC niche using a more biomimetic in vitro model. We have taken a 
basic research process and refined it for translational use so that it has the potential to be delivered to 
patients to treat ocular surface failure within the next two years.  
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